Streptococcal infection observed in the Autumn of 1995

STUART SANDERS

SUMMARY

Near patient testing demonstrated an unusual infection pattern with a high incidence of Lancefield group D β -haemolytic streptococci in patients with pharyngitis and tonsillitis in a London general practice. This raises questions regarding the epidemiology of this streptococcus strain, which is not usually associated with upper respiratory infections.

Keywords: upper respiratory tract infection; near patient testing.

Introduction

THE β -haemolytic streptococcus (β HS) is recognized as a cause of sore throat and tonsillitis as well as other serious delayed effects.

Following a previous study of upper respiratory infections in a study carried out in a London general practice in 1968, near patient testing for pathogenic bacteria and their antibiotic sensitivity pattern was instituted in my practice in 1970. This report describes an unusual infection cluster abstracted from an FRCGP Fellowship by Assessment (FBA6) presentation.

Methods

The patients were drawn from a central London private general practice comprising 514 male and 592 female patients. The age-sex distribution of the practice is similar to that of the United Kingdom as a whole.

All patients presenting between 1 September 1995 and 30 November 1995 with either pharyngitis (sore throat with hyperaemia of the fauces) or tonsillitis (enlarged tonsils with hyperaemia, pus, and fever) had a throat culture taken; this was cultured overnight at 37°C on a blood agar plate in the practice laboratory before antibiotic treatment was considered. Between 1 and 30 November 1995, positive cultures containing haemolytic species were further subjected to Lancefield grouping using a standard antigen-agglutination technique. All patients shown to have a β HS were prescribed phenoxymethyl penicillin for five days, as recommended in the British National Formulary, and check cultures were taken at the end of this treatment course.

Results

During September and October 1995, 33 throat cultures were processed and 13 were shown to contain haemolytic streptococcus species. Consequently, during November 1995, 42 cases of pharyngitis or tonsillitis were subjected to more detailed study. Eighteen cultures grew haemolytic species and these were sent to a reference laboratory for Lancefield grouping: eight were found to be groupable bacteria and the positive results are summarized in Table 1.

S Sanders, MBChB, FRCGP, general practitioner, Harley Street, London. Submitted: 18 December 1996; accepted: 11 September 1997.

© British Journal of General Practice, 1998, 48, 989-990.

Sixteen patients were subsequently re-examined to confirm that the β HS had been eradicated, and 14 were confirmed as being free from infection.

In the three-month period from September to November 1995, 75 patients presented with throat infections; on re-audit during the period January to March 1966, 27 throat infections were seen in the practice and, of these, five cultures contained haemolytic species. This dramatic decrease in streptococcal isolations led to the conclusion that there had been a local increased incidence of β HS infections.

Discussion

The commonest pathogenic β HS is the Lancefield group A bacterium, with a minority of pathogens belonging to groups B, C, and G. Group D streptococci usually cause wound infection, soft tissue infection, and internal infections as opposed to the other groups that predominantly cause throat infections.³ An unexpected observation was that five of the eight bacteria positively identified in this study were group D β HS, and this leads to the conclusion that this bacterium was probably the cause of a significant proportion of upper respiratory infections in the practice patients.

In this study, 42 cases of pharyngitis or tonsillitis were examined bacteriologically and β HS were isolated in 19% of these. This should be compared with Sanders and Norman,⁴ who reported 21% β HS isolations in throat cultures. Howe *et al*⁵ demonstrated that 32% of their patients were infected with a β HS. It is clear that the streptococcus remains a prevalent bacterium causing upper respiratory infections.

Treatment of streptococcal infections is a subject of debate. Current practice in the United Kingdom is clearly stated in the British National Formulary: 'It (phenoxymethyl penicillin) is indicated principally for respiratory tract infections in children, for streptococcal infections...' However, Howe et al⁵ recently concluded that cefixime is the treatment of choice.

The unusual finding of a high incidence of group D β HS in throat infections is worthy of note, raises unanswered questions, and forms a basis for further studies in the epidemiology of β HS infections. The study also illustrates the potential of near patient testing propounded by Hobbs.⁶

References

- Sanders S. Febrile children in a London practice. Clin Paediatr 1968; 7: 574-576
- British National Formulary. [Number 33.] London: BMA & Royal Pharmaceutical Society of Great Britain, 1997.
- Merck Manual of Diagnosis and Therapy. 16th edn. Rahway, USA: Merck & Co Inc, 1992.
- Sanders S, Norman AP. The bacterial flora of the upper respiratory tract. J Allergy 1992; 41: 319-325.
- Howe RW, Millar MR, Coast J, et al. A randomized controlled trial of antibiotics on symptom resolution in patients presenting to their general practitioner with a sore throat. Br J Gen Pract 1997; 47: 280-284.
- 6. Hobbs R. Near patient testing in primary care. *BMJ* 1996, **312**: 263-264.

Address for correspondence

Dr S Sanders, 22 Harmont House, 20 Harley Street, London W1N 1AL.

S Sanders Brief reports

Table 1. Number of positive cultures containing haemolytic species after Lancefield grouping.

Lancefield group	Positive cultures	
A	0	
В	2	
С	0	
D	5	
E	0	
F	1	

Acknowledgement

I thank Dr Paul Davis, my FBA6 adviser, for his unstinting support and encouragement.

GP Out of Hours Triage

HART - 24 HR NURSE Call Centre



- save money
- ◆ most comprehensive information system available in the UK
- ◆ professional means to handle your PT's needs
- ♦ specialists in health information and services via telephone we have the time to listen

0171 481 8190

for more information call - Jenn Davies

HEALTHCARE ADMINISTRATION RESOURCES & TECHNOLOGY



The Royal Institute of Public Health and Hygiene and Society of Public Health 28 Portland Place, London W1N 4DE

OCCUPATIONAL MEDICINE - DIPLOMA COURSE

5th October - 16th October 1998

This ten day course is designed for General Practitioners seeking foundation training in occupational medicine with a view to obtaining the Faculty of Occupational Medicine's Diploma in Occupational Medicine.

The course, which is Faculty approved, will prepare candidates for the December 1998 Diploma written examination. PGEA approval has been obtained and the course will be run at 28 Portland Place, London

Distinguished speakers from a wide range of occupational medicine, occupational health and academic backgrounds will cover all aspects of the Faculty's Diploma syllabus.

Visits to commercial and industrial sites are included in the course.

The course fee is £945 and includes tuition, all course materials, lunch and refreshments.

For further details please contact:

Ms Geri Maylin, Education & Training Department, RIPHH, 28 Portland Place, London W1N 4DE. Tel: 0171 580 2731 Fax: 0171 580 6157 Email: riphh@corpex.com

HEALTH CARE SERVICE FOR PRISONERS



The Service provides medical care for prisoners to a standard equivalent to that in the National Health Service, and employs over 250 doctors, both full time and part time.

A programme of training is provided which recognises the specialist nature of medical work in prisons to include management: the syllabus leads to the acquisition of a Diploma in Prison Medicine.

All facilities and equipment are provided and all employed doctors are indemnified by the Service. Prison medicine is a challenging and rewarding area of medical practice. Vacancies exist both for full time and part time posts in many parts of England and Wales.

Doctors who are interested are invited to write or speak to:

Dr Roy Burrows, Directorate of Health Care, Cleland House, Page Street, London SW1P 4LN, Tel: 0171-217 6550.

Fax: 0171-217 6412.